When you're diagnosed with a type of lung cancer driven by a specific genetic glitch called a KRAS mutation, your treatment options have been limited. A new, early-stage trial tested a two-drug combination—fulzerasib pills plus an IV drug called cetuximab—in people who hadn't yet received any treatment for their advanced cancer. The goal was to see if it could shrink tumors.
In 47 patients across Europe, the results were promising: about 69% of people saw their tumors shrink significantly, which doctors call an 'objective response.' The treatment was also manageable for most. While most patients had some side effects, severe ones were less common, and no life-threatening side effects were directly tied to the drugs. A small number of people had to stop one of the drugs because of these effects.
It's important to remember this is very early data. The study was small and didn't compare this combination to the current standard of care. We don't know yet if it helps people live longer or feel better. The results are a positive signal that warrants larger, more definitive studies to see if this could become a real option for patients.
